Brown Advisory Inc. increased its stake in Biohaven Ltd. (NYSE:BHVN - Free Report) by 4.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,020,117 shares of the company's stock after buying an additional 44,532 shares during the quarter. Brown Advisory Inc. owned about 1.00% of Biohaven worth $24,524,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Parallel Advisors LLC boosted its stake in shares of Biohaven by 319.8% during the 1st quarter. Parallel Advisors LLC now owns 1,360 shares of the company's stock worth $33,000 after purchasing an additional 1,036 shares during the period. KBC Group NV lifted its stake in Biohaven by 35.0% in the first quarter. KBC Group NV now owns 4,560 shares of the company's stock worth $110,000 after purchasing an additional 1,183 shares during the last quarter. US Bancorp DE boosted its position in shares of Biohaven by 36.7% during the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after buying an additional 798 shares during the period. Quarry LP bought a new position in shares of Biohaven during the fourth quarter valued at approximately $112,000. Finally, Lazard Asset Management LLC raised its holdings in shares of Biohaven by 47.4% in the fourth quarter. Lazard Asset Management LLC now owns 3,207 shares of the company's stock worth $119,000 after buying an additional 1,031 shares during the period. 88.78% of the stock is owned by hedge funds and other institutional investors.
Biohaven Price Performance
NYSE BHVN traded down $1.14 during midday trading on Friday, hitting $13.89. 1,700,279 shares of the company traded hands, compared to its average volume of 1,309,333. Biohaven Ltd. has a 52 week low of $13.75 and a 52 week high of $55.70. The company's 50-day simple moving average is $15.94 and its 200-day simple moving average is $25.94. The company has a market cap of $1.42 billion, a PE ratio of -1.48 and a beta of 0.91.
Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($2.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.50). On average, research analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on BHVN shares. Royal Bank Of Canada cut Biohaven from an "outperform" rating to a "sector perform" rating and dropped their price objective for the company from $54.00 to $21.00 in a report on Monday, May 19th. William Blair raised shares of Biohaven to a "strong-buy" rating in a research note on Thursday, April 24th. Robert W. Baird reduced their price target on shares of Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a research note on Monday, April 28th. JPMorgan Chase & Co. decreased their price objective on shares of Biohaven from $68.00 to $55.00 and set an "overweight" rating for the company in a report on Wednesday, June 18th. Finally, Cantor Fitzgerald upgraded shares of Biohaven to a "strong-buy" rating in a research note on Tuesday, May 13th. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $58.46.
Read Our Latest Research Report on Biohaven
About Biohaven
(
Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Featured Articles
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
